Skip to main content
SpringerLink
Log in

Extrahepatic Manifestations of Hepatitis C Virus Infection

  • Chapter
  • First Online:
Hepatitis C: Care and Treatment

  • 282 Accesses

Abstract

Approximately 130–170 million people are infected with hepatitis C virus (HCV) worldwide and 2.35% of the total world population. HCV infection induces tremendous morbidity and mortality mainly due to liver complications (cirrhosis, hepatocellular carcinoma) and significant direct medical costs. In addition, HCV is associated to a large number of extrahepatic manifestations, including cardiovascular diseases, type 2 diabetes and insulin resistance, neurocognitive dysfunction, systemic vasculitis, B cell non-Hodgkin lymphoma and chronic kidney disease. The recent emergence of new direct acting interferon-free antivirals (DAA), enabling high cure rates with a good safety profile, should benefit also many patients presenting HCV extrahepatic complications. Multidisciplinary consensus recommends considering as first-line treatment IFN-free DAAs for HCV patients with significant liver fibrosis and extrahepatic complications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cacoub P, Buggisch P, Carrión JA, Cooke GS, Zignego AL, Beckerman R, et al. Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe. J Viral Hepat. 2018;25(7):811–7.

    Article  CAS  PubMed  Google Scholar 

  2. Cacoub P, Vautier M, Desbois AC, Saadoun D, Younossi Z. Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France. Aliment Pharmacol Ther. 2018;47:123–8.

    Article  CAS  PubMed  Google Scholar 

  3. Cacoub P, Vautier M, Desbois AC, Lafuma A, Saadoun D. Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: from interferon-based to direct-acting antivirals era. Liver Int Off J Int Assoc Study. Liver. 2017;37:1805–13.

    CAS  Google Scholar 

  4. Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2014;46(Suppl 5):S165–73.

    Google Scholar 

  5. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum. 1999;42:2204–12.

    Article  CAS  PubMed  Google Scholar 

  6. Trejo O, Ramos-Casals M, García-Carrasco M, Yagüe J, Jiménez S, De la red G, et al. Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore). 2001;80:252–62.

    Article  CAS  Google Scholar 

  7. Terrier B, Cacoub P. Cryoglobulinemia vasculitis: an update. Curr Opin Rheumatol. 2013;25:10–8.

    Article  PubMed  Google Scholar 

  8. Desbois AC, Comarmond C, Saadoun D, Cacoub P. Cryoglobulinemia vasculitis: how to handle. Curr Opin Rheumatol. 2017;29:343–7.

    Article  CAS  PubMed  Google Scholar 

  9. Cacoub P, Comarmond C, Desbois AC, Saadoun D. Rheumatologic manifestations of hepatitis C virus infection. Clin Liver Dis. 2017;21:455–64.

    Article  PubMed  Google Scholar 

  10. Musset L, Diemert MC, Taibi F, Du LTH, Cacoub P, Leger JM, et al. Characterization of cryoglobulins by immunoblotting. Clin Chem. 1992;38:798–802.

    Article  CAS  PubMed  Google Scholar 

  11. Terrier B, Semoun O, Saadoun D, Sène D, Resche-Rigon M, Cacoub P. Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. Arthritis Rheum. 2011;63:1748–57.

    Article  PubMed  Google Scholar 

  12. Landau D-A, Scerra S, Sene D, Resche-Rigon M, Saadoun D, Cacoub P. Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy. J Rheumatol. 2010;37:615–21.

    Article  CAS  PubMed  Google Scholar 

  13. Ferri C, Sebastiani M, Giuggioli D, Cazzato M, Longombardo G, Antonelli A, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum. 2004;33:355–74.

    Article  PubMed  Google Scholar 

  14. Park H, Adeyemi A, Henry L, Stepanova M, Younossi Z. A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection. J Viral Hepat. 2015;22:897–905.

    Article  CAS  PubMed  Google Scholar 

  15. Hsu Y-C, Ho HJ, Huang Y-T, Wang H-H, Wu M-S, Lin J-T, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64:495–503.

    Article  CAS  PubMed  Google Scholar 

  16. Chen Y-C, Hwang S-J, Li C-Y, Wu C-P, Lin L-CA. Taiwanese nationwide cohort study shows interferon-based therapy for chronic hepatitis C reduces the risk of chronic kidney disease. Medicine (Baltimore). 2015;94:e1334.

    Article  CAS  Google Scholar 

  17. Fabrizi F, Verdesca S, Messa P, Martin P. Hepatitis C Virus infection increases the risk of developing chronic kidney disease: a systematic review and meta-analysis. Dig Dis Sci. 2015;60:3801–13.

    Article  PubMed  Google Scholar 

  18. Desbois A-C, Cacoub P. Diabetes mellitus, insulin resistance and hepatitis C virus infection: a contemporary review. World J Gastroenterol. 2017;23:1697–711.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology. 2017;152:142–56.

    Article  PubMed  Google Scholar 

  20. Domont F, Cacoub P. Chronic hepatitis C virus infection, a new cardiovascular risk factor? Liver Int Off J Int Assoc Study Liver. 2016;36:621–7.

    Google Scholar 

  21. Ferri C, Ramos-Casals M, Zignego AL, Arcaini L, Roccatello D, Antonelli A, et al. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev. 2016;15:1145–60.

    Article  PubMed  Google Scholar 

  22. Vannata B, Arcaini L, Zucca E. Hepatitis C virus-associated B-cell non-Hodgkin’s lymphomas: what do we know? Ther Adv Hematol. 2016;7:94–107.

    Article  CAS  PubMed  Google Scholar 

  23. Couronné L, Bachy E, Roulland S, Nadel B, Davi F, Armand M, et al. From hepatitis C virus infection to B-cell lymphoma. Ann Oncol Off J Eur Soc Med Oncol. 2018;29:92–100.

    Article  Google Scholar 

  24. Khaled H, Abu-Taleb F, Haggag R. Hepatitis C virus and non-Hodgkin’s lymphomas: a minireview. J Adv Res. 2017;8:131–7.

    Article  CAS  PubMed  Google Scholar 

  25. Persico M, Aglitti A, Caruso R, De Renzo A, Selleri C, Califano C, et al. Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin’s lymphoma. Hepatol Baltim Md. 2018;67:48–55.

    Article  CAS  Google Scholar 

  26. Allison RD, Tong X, Moorman AC, Ly KN, Rupp L, Xu F, et al. Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006–2010. J Hepatol. 2015;63:822–8.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud-Ratti V, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d’Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l’Hepatite C. Medicine (Baltimore). 2000;79:47–56.

    Article  CAS  Google Scholar 

  28. Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2010;8:1017–29.

    Google Scholar 

  29. Golabi P, Sayiner M, Bush H, Gerber LH, Younossi ZM. Patient-reported outcomes and fatigue in patients with chronic hepatitis C infection. Clin Liver Dis. 2017;21:565–78.

    Article  PubMed  Google Scholar 

  30. Adinolfi LE, Nevola R, Rinaldi L, Romano C, Giordano M. Chronic hepatitis C virus infection and depression. Clin Liver Dis. 2017;21:517–34.

    Article  PubMed  Google Scholar 

  31. Monaco S, Mariotto S, Ferrari S, Calabrese M, Zanusso G, Gajofatto A, et al. Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: advances in 2015. World J Gastroenterol. 2015;21:11974–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Ramos-Casals M, Loustaud-Ratti V, De Vita S, Zeher M, Bosch J-A, Toussirot E, et al. Sjögren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases. Medicine (Baltimore). 2005;84:81–9.

    Article  Google Scholar 

  33. Brito-Zerón P, Gheitasi H, Retamozo S, Bové A, Londoño M, Sánchez-Tapias J-M, et al. How hepatitis C virus modifies the immunological profile of Sjögren syndrome: analysis of 783 patients. Arthritis Res Ther. 2015;17:250.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Koike K, Moriya K, Ishibashi K, Yotsuyanagi H, Shintani Y, Fujie H, et al. Sialadenitis histologically resembling Sjogren syndrome in mice transgenic for hepatitis C virus envelope genes. Proc Natl Acad Sci U S A. 1997;94:233–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Verbaan H, Carlson J, Eriksson S, Larsson A, Liedholm R, Manthorpe R, et al. Extrahepatic manifestations of chronic hepatitis C infection and the interrelationship between primary Sjögren’s syndrome and hepatitis C in Swedish patients. J Intern Med. 1999;245:127–32.

    Article  CAS  PubMed  Google Scholar 

  36. Saadoun D, Rigon MR, Pol S, Thibault V, Blanc F, Pialoux G, et al. PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. J Hepatol. 2015;62:24–30.

    Article  CAS  PubMed  Google Scholar 

  37. Virlogeux V, Pradat P, Bailly F, Funingana G, Gonçalves F, Maynard M, et al. Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score. J Viral Hepat. 2014;21:e98–107.

    Article  CAS  PubMed  Google Scholar 

  38. Saadoun D, Pol S, Ferfar Y, Alric L, Hezode C, Si Ahmed SN, et al. Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis. Gastroenterology. 2017;153:49–52.e5.

    Article  CAS  PubMed  Google Scholar 

  39. Saadoun D, Thibault V, Si Ahmed SN, Alric L, Mallet M, Guillaud C, et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis [Internet]. 2015 [cited 2016 Mar 28]. http://ard.bmj.com/cgi/doi/10.1136/annrheumdis-2015–208339

  40. Sise ME, Bloom AK, Wisocky J, Lin MV, Gustafson JL, Lundquist AL. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. Feb. 2015;63:408–17. https://doi.org/10.1002/hep.28297.

    Article  CAS  PubMed  Google Scholar 

  41. Gragnani L, Visentini M, Fognani E, Urraro T, Santis A, Petraccia L. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology. 2016;64(5):1473–82.

    Article  CAS  PubMed  Google Scholar 

  42. Kondili LA, Weimer LE, Mallano A, Fucili L, Massella M, Vinci M, et al. HCV-related mixed cryoglobulinemia: data from PITER, a nationwide Italian HCV cohort study. J Hepatol. 2016;64:S618.

    Article  Google Scholar 

  43. Emery J, Kuczynski M, La D, Almarzooqi S, Kowgier M, Shah H, et al. Treatment of hepatitis C associated mixed cryoglobulinemia with direct acting antivirals. J Hepatol. 2016;64:S779.

    Article  Google Scholar 

  44. De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:843–53.

    Article  PubMed  CAS  Google Scholar 

  45. Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:835–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Saadoun D, Resche Rigon M, Sene D, Terrier B, Karras A, Perard L, et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood. 2010;116:326–34.

    Article  CAS  PubMed  Google Scholar 

  47. Dammacco F, Tucci FA, Lauletta G, Gatti P, De Re V, Conteduca V, et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood. 2010;116:343–53.

    Article  CAS  PubMed  Google Scholar 

  48. European Association for Study of Liver. EASL Recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199–236.

    Article  Google Scholar 

  49. Ramos-Casals M, Zignego AL, Ferri C, Brito-Zerón P, Retamozo S, Casato M, Lamprecht P, Mangia A, Saadoun D, Tzioufas AG, Younossi ZM, Cacoub P. International study group of extrahepatic manifestations related to HCV (ISG-EHCV). Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. J Hepatol. 2017;66(6):1282–99.

    Google Scholar 

  50. Cacoub P, Desbois AC, Isnard-Bagnis C, Rocatello D, Ferri C. Hepatitis C virus infection and chronic kidney disease: time for reappraisal. J Hepatol. 2016;65:S82–94.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sorbonne Université, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Paris, France

    Anne Claire Desbois & Patrice Cacoub

  2. INSERM, UMR_S 959, Paris, France

    Anne Claire Desbois & Patrice Cacoub

  3. CNRS, FRE3632, Paris, France

    Anne Claire Desbois & Patrice Cacoub

  4. AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, Paris, France

    Anne Claire Desbois & Patrice Cacoub

Authors
  1. Anne Claire Desbois
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrice Cacoub
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrice Cacoub .

Editor information

Editors and Affiliations

  1. Department of Hygiene, Epidemiology and Medical Statistics, National and Kapodistrian University of Athens Medical School, Athens, Greece

    Angelos Hatzakis

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Desbois, A.C., Cacoub, P. (2021). Extrahepatic Manifestations of Hepatitis C Virus Infection. In: Hatzakis, A. (eds) Hepatitis C: Care and Treatment . Springer, Cham. https://doi.org/10.1007/978-3-030-67762-6_2

Download citation

Publish with us

Policies and ethics

Search

Navigation